Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from GSK

Unilever rules out big acquisitions after failed £50bn GSK consumer bid

The consumer giant also signalled that customers will continue to face higher prices amid efforts to control spiralling costs.

The Independent UK

Wall Street drops as interest rate rises loom after US inflation hits 7.5% – as it happened

Rolling coverage of the latest economic and financial news

The Guardian - UK

Noisy activists aside, GSK investors backed Walmsley and her strategy

The ‘step-change’ in growth for the core pharma division has barely started, but the CEO is secure for now

The Guardian - UK

From analysis to the latest developments in health,
read the most diverse news in one place.

GlaxoSmithKline: Q4 Earnings Insights

GlaxoSmithKline (NYSE:GSK) reported its Q4 earnings results on Wednesday, February 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Benzinga

Glaxo's Q4 Pharma Sales Jump 20% Boosted By COVID-19 Treatment; Prepares For Spin-Off

GlaxoSmithKline Plc's (NYSE: GSK) turnover was

Benzinga

GSK boss pledges ‘landmark year’ as pharma firm pursues demerger

Results better than forecast but Emma Walmsley is under pressure from activist investors clamouring for change

The Guardian - UK

Cost of living crisis hits household confidence; UK trade with Germany falls; FTSE 100 at two-year high – as it happened

Rolling coverage of the latest economic and financial news

The Guardian - UK

Read news from The Economist, FT, and more,
with one subscription

Deborah Waterhouse: ‘The HIV stigma remains, and this is a battle we’ve got to fight’

The GSK executive has found her niche at ViiV Healthcare developing HIV drugs, and is optimistic a cure will be found

The Guardian - UK

GSK To Get $1.25B As Settlement For HIV Treatment Drug Patent Row With Gilead

GlaxoSmithKline plc (NYSE: GSK) has settled a patent dispute between ViiV Healthcare and Gilead Sciences Inc (NASDAQ: GILD).

Benzinga

GSK claims $1.2bn victory in HIV patent battle with US rival Gilead

Drugmaker GlaxoSmithKline today claimed a landmark victory in its competitive battle to dominate HIV treatment as a US rival agreed to hand over $1.25 billion to end a high-stakes global patent dispute.

Evening Standard

FDA Approves First Injectable For HIV Pre-Exposure Prevention - GSK, Pfizer Backed Treatment

The FDA has approved ViiV Healthcare's Apretude (cabotegravir extended-release injectable suspension

Benzinga

Unilever: why the maker of Marmite is feeling the squeeze

As a major manufacturer of well known cleaning products, it is perhaps fitting that events at Unilever have started to resemble something of a corporate soap opera. In the last few weeks there has been increased pressure at the top, a failed merger attempt, backlash from investors, and an announcement…

The Conversation

Pressure for shake-up expected at Unilever as activist investor buys stake in firm

Nelson Peltz’s hedge fund takes position in company thrown into turmoil after £50bn offer for a division of GSK

The Guardian - UK

Time for Unilever boss to concede lack of appetite for a big tilt

Shake-up will have to be gradual, and deal-making on a smaller scale needn’t be off the table

The Guardian - UK

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - UK

Top investor castigates Unilever after failed £50bn bid for GSK arm

Terry Smith says bosses must focus on improving core business or step down after ‘near-death experience’

Evening Standard

City comment: Unilever CEO Alan Jope is walking a tightrope after GSK tilt

Questions remain about strategy despite the GSK climbdown

The Guardian - UK

UK households hit by rising cost of living; Omicron lifts US jobless claims to three-month high – as it happened

Rolling coverage of the latest economic and financial news

Bangkok Post

Unilever won't up £50bn offer for GSK-Pfizer unit

LONDON: Consumer goods giant Unilever on Wednesday said it would not increase a £50-billion offer for the consumer healthcare unit owned by pharmaceutical groups GlaxoSmithKline and Pfizer.

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - UK

Big questions for Unilever board after GSK pursuit ends

Delivering a minor heart attack to the share price, however temporarily, is not a good look

The Guardian - UK

Unilever will not increase £50bn offer for GSK consumer arm

Company says data shared by GSK suggests ‘fundamental value’ of business no higher than offer

The Independent UK

Unilever won't top $68B bid for GSK consumer healthcare unit

Unilever, the maker of Vaseline skin care products and Dove soap, says it won’t increase a 50 billion-pound ($68.2 billion) offer for GlaxoSmithKline’s consumer healthcare unit that was rejected last week

Evening Standard

Unilever vows not to increase GSK bid

Unilever has effectively ruled out a fourth takeover approach for GlaxoSmithKline’s consumer healthcare business after vowing not to increase its offer.

The Guardian - UK

GSK’s top scientist jumps ship in new blow for pharmaceutical firm

Hal Barron to leave just as pressure builds on GSK to come up with new medicines

The Guardian - UK

UK inflation jumps to 30-year high of 5.4% as cost of living crisis deepens – as it happened

Food prices, furniture, clothes and housing costs rise; unions urge government to tackle cost of living crisis as pressure builds for February rate hike

The Guardian - UK

Little ingenuity needed to spot the weakness of THG

The value of the e-commerce firm’s ‘end-to-end technology solutions’ doesn’t seem clear – no wonder investors went cold

1 … 13 14 15 16

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Office for National Statistics

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.